The Tumor Microenvironment encompasses the healthy cells, molecules, and blood vessels that surround cancer, providing nutrients and blood to support tumor growth. A tumor can alter its microenvironment in order to promote growth and progression. An Inflammatory Tumor Microenvironment contains molecules, including inflammatory cytokines (like interferons, and IL-6) and inflammatory immune cells (like myeloid-derived suppressor cells and tumor associated macrophages).
-
APR 25, 2023 | 8:00 AM
C.E. CREDITS
Date: April 25, 2023 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Several promising immunotherapies have emerged in recent decades due to advances in cancer immunology. The paradigm o...
Date: October 13, 2022 Time: 10:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Most known immune checkpoints exert their effects upon protein-protein interactions, such as the PD1 checkpoint on CD...
Date: July 12, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) Dendritic cells (DCs) are a heterogeneous population of myeloid immune cells that act as peripheral sentinels specializin...
Date: November 09, 2021 Time: 8:00am (PDT), 11:00am (EDT) Myeloid cells comprise many subsets with diverse functions. They play an important role in health and diseases such as infections, c...
Despite the promising results with current approved immunotherapies, all patients do not have the same level of response, and recent efforts have focused on understanding and avoiding immuno...
DATE: October 20th, 2020 TIME: 08:00am PT, 11:00am ET Tumor-associated macrophages (TAMs) are key cells in the tumor microenvironment (TME) with diverse immune functions that have a major in...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Speaker TBD 10:30–10:50 am PDT Exploring the immune tumor microenvironment of hepatocellular carcinoma with Imaging Mass Cytometry™ 10:50 am–11:10 am PDT Presented By: Won...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
Learning Objectives: 1. Define applications of approved and experimental (multiplexing IF) biomarker assessment in Immuno-Oncology 2. Define bottlenecks and areas of improvement to current t...